enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Core Viewpoint - enGene Holdings Inc. has appointed Dr. Hussein Sweiti as Chief Medical Officer, effective September 29, 2025, bringing over 15 years of experience in oncology and drug development [1]. Company Summary - enGene Holdings Inc. is a clinical-stage, non-viral genetic medicine company [1]. - The new Chief Medical Officer, Dr. Sweiti, has a background as a surgical oncologist and physician-scientist [1]. - Dr. Sweiti's expertise includes clinical practice, oncology clinical research, global drug development, regulatory submissions, and medical affairs [1].